Pubblished on Nature a study from Memorial Sloan-Kettering Cancer Center, New York e del Jonsson Comprehensive Cancer Center, University of California at Los Angeles. The authors found that a subset of cells resistant to vemurafenib (PLX4032, RG7204) express a 61-kDa variant form of BRAF(V600E), p61BRAF(V600E), which lacks exons 4–8, a region that encompasses the RAS-binding domain. p61BRAF(V600E) shows enhanced dimerization in cells with low levels of RAS activation, as compared to full-length BRAF(V600E)
Read more: RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
